Chicago，USA September 1, 2020 Sparx Therapeutics, an emerging biopharmaceutical company specializing in developing multi-specific antibodies to treat solid tumors, today announced the appointment of Dr. Victor Wroblewski, a former Eli Lilly veteran, as a Senior VP and Head of Biology. Dr. Victor Wroblewski brings in decades of deep knowledge and experience in antibody drug development.…
SPARX TECHNOLOGIES
Big Data-Aided Target Mining
Target validation remains a bottleneck for the development of innovative medicines, primarily due to the complexity of the biology and pathology of a given disease. The true link between a disease and a molecular target is still largely established in late stage clinical trials.
Read More
Antibody Phage Display
Developed by GP Smith (2018 Nobel Laureate in Chemistry), phage display technique has been widely used in peptide, protein, as well as antibody engineering. Encapsulating the ssDNA gene, phage particles display the protein encoded by the gene on the surface, providing a physical linkage between phenotype and genotype.
Read More
Hybridoma Antibody Discovery
The hybridoma technology is a traditional but still widely used method to produce monoclonal antibodies. The B lymphocytes secrete monoclonal antibodies but cannot replicate themselves in culture. On the other hand, the myeloma cells do not produce antibody but can replicate in culture easily.
Read More
Sparx MULCOMTM
Sparx Multi-Component Nanotechnology Platform – SPARX MULCOMTM – is an advanced drug delivery polymer-lipid hybrid technology designed to deliver multiple drugs and biologics for combination therapy. With our SPARX MULCOMTM, stable nanoparticles encapsulating molecules with multiple properties within the same particle via self-assembly processes are formed.
Read More
LEMMAbTM
LEMMAbTM (Linker Enhanced Mono-chained Multi-specific Antibody) is our proprietary technology platform that uses natural IgG with Fc in constructing bispecific or multi-specific antibody for cutting-edge biomedical research and development. Owing to the single chain and symmetrical nature, LEMMAbTM antibodies resulting from this technology are free of mismatches, more soluble, less prone to aggregate, simpler to purify, and expressed in higher yield. These types of antibodies tend to have decreased immunogenicity and improved binding affinity, safety profiles, and developability.
Read More
Sparx SMARTOPTM
SMARTOPTM (Symmetric Multispecific Antibodies with Relative-affinities fine-Tuned by phage Off-rate and PH-selections) is another proprietary antibody research and development platform in the field of bispecific or multi-specific antibody construction. SMARTOPTM shares several features with LEMMAbTM and this type of antibodies are also symmetrical and free of mismatches, more soluble, less prone to aggregate, simpler to purify, and expressed in higher yield. In addition, SMARTOPTM antibodies are selected by slower off-rate and better tolerance for the lower pH values in tumor microenvironment. As a result, this type of antibodies tends to have improved tumor retention and more tailored target engaging kinetics. They also enjoy decreased immunogenicity and improved binding affinity, safety profiles, and developability.
Read More
DEVELOPMENT PIPELINE
Equipped with critical technologies for pharmaceutical innovations, such as the Big Data-Aided Target Mining Technology, Antibody Phage Display and Hybridoma Antibody Discovery technologies, as well as the Sparx Multi-Component Nanotechnology Platform – SPARX MULCOMTM, Sparx has generated a rich development pipeline for the treatment of cancer and CNS diseases.
News Center
Sparx Therapeutics-News release 2018-11-8
Sparx Therapeutics & KPC Pharmaceutical Sign Agreement for the Development of anti-Claudin 18.2 Antibodies Sparx Therapeutics, Inc. has signed an agreement with KPC Pharmaceutical to discover and develop a monoclonal antibody against Claudin 18.2 with the potential to treat a range of human diseases including gastric cancer. Under the terms of the agreement, Sparx will…